EMD Serono

Richard R. Smith joins EMD Serono as SVP and head of US Fertility and Endocrinology

Wednesday, January 18, 2017

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, has announced that Richard R. Smith joined the company as senior vice president and head of U.S. Fertility and Endocrinology. In this role, Mr. Smith will oversee the Fertility and Endocrinology businesses in the U.S., including the U.S. Fertility Technologies division, which launched its first product last year with Gidget, a hand-held witnessing system for the IVF laboratory that provides visual lab workflow management and support for traceability and audit reporting.

[Read More]

INC Research and CISCRP name C2 winner of Inspiring Hope Ideathon

Thursday, September 29, 2016

INC Research Holdings, a global phase I to IV CRO, together with the Center for Information and Study on Clinical Research Participation (CISCRP), a nonprofit organization dedicated to engaging the public and patients as partners in the clinical research process, has announced Team “C2: The Clinical Study Change Agent Collective” was chosen as the winner of the 2016 “Inspiring Hope” Ideathon.

[Read More]

EMD Serono appoints Craig Millian SVP, Neurology And Immunology

Tuesday, September 20, 2016

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, has announced the appointment of Craig Millian as senior vice president, Neurology and Immunology. Millian most recently served as senior vice president, head of U.S. Fertility and Endocrinology at EMD Serono. In his new role, he will lead the strategic direction of the company’s U.S. Neurology and Immunology franchise.

[Read More]

EMD Serono to open $115M life science campus in Massachusetts

Tuesday, July 19, 2016

EMD Serono, known as Merck outside of the U.S. and Canada, a science and technology company, has announced plans to build a new campus in Burlington, Massachusetts, that will serve as a major hub for the North American life science business of Merck. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space.

[Read More]

EMD Serono expands biopharmaceutical R&D facility in Massachusetts

Tuesday, May 3, 2016

EMD Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, in North America, has announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.

[Read More]

EMD Serono appoints U.S. CMO

Wednesday, September 30, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.

[Read More]

Advisory boards amplify patients’ voices

Tuesday, September 15, 2015

A strong and growing desire to solicit feedback directly from patients, ex­perienced participants and their sup­port network is prompting many sponsors and CROs to assess, plan and implement patient advisory panels.

[Read More]